Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 17

1.

Lys(199) mutation of the human angiotensin type 1 receptor differentially affects the binding of surmountable and insurmountable non-peptide antagonists.

Fierens FL, Vanderheyden PM, Gáborik Z, Minh TL, Backer JP, Hunyady L, Ijzerman A, Vauquelin G.

J Renin Angiotensin Aldosterone Syst. 2000 Sep;1(3):283-8.

PMID:
11881039
2.

Long-lasting angiotensin type 1 receptor binding and protection by candesartan: comparison with other biphenyl-tetrazole sartans.

Vauquelin G, Fierens F, Van Liefde I.

J Hypertens Suppl. 2006 Mar;24(1):S23-30. Review.

PMID:
16601569
3.
4.

How can the differences among AT1-receptor antagonists be explained?

Morsing P, Vauquelin G.

Cell Biochem Biophys. 2001;35(1):89-102. Review.

PMID:
11898857
5.

Newly emerging pharmacologic differences in angiotensin II receptor blockers.

Oparil S.

Am J Hypertens. 2000 Jan;13(1 Pt 2):18S-24S. Review.

PMID:
10678284
6.
7.

AT1 receptor antagonists.

Verheijen I, Vanderheyden PM, De Backer JP, Vauquelin G.

Curr Med Chem Cardiovasc Hematol Agents. 2004 Jan;2(1):69-77. Review.

PMID:
15320808
9.

Molecular determinants of peptide and non-peptide binding to the AT1 receptor.

Karnik SS, Husain A, Graham RM.

Clin Exp Pharmacol Physiol Suppl. 1996;3:S58-66. Review.

PMID:
8993841
10.

Sartan-AT1 receptor interactions: in vitro evidence for insurmountable antagonism and inverse agonism.

Van Liefde I, Vauquelin G.

Mol Cell Endocrinol. 2009 Apr 29;302(2):237-43. doi: 10.1016/j.mce.2008.06.006. Epub 2008 Jun 21. Review.

PMID:
18620019
11.

Pharmacological properties of angiotensin II receptor antagonists.

Timmermans PB.

Can J Cardiol. 1999 Nov;15 Suppl F:26F-8F. Review.

PMID:
10579749
12.

Pharmacologic properties of candesartan cilexetil--possible mechanisms of long-acting antihypertensive action.

Inada Y, Ojima M, Kanagawa R, Misumi Y, Nishikawa K, Naka T.

J Hum Hypertens. 1999 Jan;13 Suppl 1:S75-80. Review.

PMID:
10076925
13.

AT(1)-receptor blockers: differences that matter.

Gradman AH.

J Hum Hypertens. 2002 Aug;16 Suppl 3:S9-S16. Review.

14.

Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension.

Israili ZH.

J Hum Hypertens. 2000 Apr;14 Suppl 1:S73-86. Review.

PMID:
10854085
15.

Dynamic mechanisms of non-classical antagonism by competitive AT(1) receptor antagonists.

Lew MJ, Ziogas J, Christopoulos A.

Trends Pharmacol Sci. 2000 Oct;21(10):376-81. Review.

PMID:
11050317
16.

A new class of diacidic nonpeptide angiotensin II receptor antagonists: candesartan cilexetil.

Naka T, Kubo K, Inada Y, Nishikawa K.

Drug Des Discov. 1999 Aug;16(2):95-108. Review.

PMID:
10533806
17.

[Pharmacological profiles of candesartan cilexetil (TCV-116)].

Inada Y.

Nihon Rinsho. 1999 May;57(5):1130-6. Review. Japanese.

PMID:
10361446

Supplemental Content

Support Center